MX2015003701A - Composiciones para tratamiento. - Google Patents

Composiciones para tratamiento.

Info

Publication number
MX2015003701A
MX2015003701A MX2015003701A MX2015003701A MX2015003701A MX 2015003701 A MX2015003701 A MX 2015003701A MX 2015003701 A MX2015003701 A MX 2015003701A MX 2015003701 A MX2015003701 A MX 2015003701A MX 2015003701 A MX2015003701 A MX 2015003701A
Authority
MX
Mexico
Prior art keywords
treatment compositions
compositions
methods
oxidative stress
treating diseases
Prior art date
Application number
MX2015003701A
Other languages
English (en)
Inventor
Daniel Robinson
james Pack
Gary Samuelson
Original Assignee
Reoxcyn Discoveries Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reoxcyn Discoveries Group Inc filed Critical Reoxcyn Discoveries Group Inc
Publication of MX2015003701A publication Critical patent/MX2015003701A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
    • C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
    • C02F1/46104—Devices therefor; Their operating or servicing
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
    • C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
    • C02F1/46104—Devices therefor; Their operating or servicing
    • C02F1/4618—Devices therefor; Their operating or servicing for producing "ionised" acidic or basic water
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
    • C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
    • C02F1/467—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
    • C02F1/469—Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
    • C02F1/4698—Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis electro-osmosis
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B9/00—Cells or assemblies of cells; Constructional parts of cells; Assemblies of constructional parts, e.g. electrode-diaphragm assemblies; Process-related cell features
    • C25B9/17—Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof
    • C25B9/19—Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof with diaphragms
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
    • C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
    • C02F1/46104—Devices therefor; Their operating or servicing
    • C02F1/46109—Electrodes
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2201/00—Apparatus for treatment of water, waste water or sewage
    • C02F2201/46—Apparatus for electrochemical processes
    • C02F2201/461—Electrolysis apparatus
    • C02F2201/46105—Details relating to the electrolytic devices
    • C02F2201/4611—Fluid flow
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2201/00—Apparatus for treatment of water, waste water or sewage
    • C02F2201/46—Apparatus for electrochemical processes
    • C02F2201/461—Electrolysis apparatus
    • C02F2201/46105—Details relating to the electrolytic devices
    • C02F2201/46115—Electrolytic cell with membranes or diaphragms
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2201/00—Apparatus for treatment of water, waste water or sewage
    • C02F2201/46—Apparatus for electrochemical processes
    • C02F2201/461—Electrolysis apparatus
    • C02F2201/46105—Details relating to the electrolytic devices
    • C02F2201/46155—Heating or cooling

Abstract

Se describen composiciones y métodos para tratar enfermedades relacionadas con estrés oxidativo.
MX2015003701A 2012-09-21 2013-02-28 Composiciones para tratamiento. MX2015003701A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261704401P 2012-09-21 2012-09-21
US201261706670P 2012-09-27 2012-09-27
US201261707141P 2012-09-28 2012-09-28
PCT/US2013/028420 WO2014046722A1 (en) 2012-09-21 2013-02-28 Treatment compositions

Publications (1)

Publication Number Publication Date
MX2015003701A true MX2015003701A (es) 2015-10-29

Family

ID=50341821

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003700A MX2015003700A (es) 2012-09-21 2012-12-07 Celda para electrolizar un liquido.
MX2015003701A MX2015003701A (es) 2012-09-21 2013-02-28 Composiciones para tratamiento.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015003700A MX2015003700A (es) 2012-09-21 2012-12-07 Celda para electrolizar un liquido.

Country Status (7)

Country Link
US (2) US9962404B2 (es)
EP (3) EP2898116A4 (es)
JP (2) JP6314142B2 (es)
CN (2) CN104903494B (es)
MX (2) MX2015003700A (es)
RU (2) RU2636483C2 (es)
WO (2) WO2014046697A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486481B2 (en) 2007-10-30 2016-11-08 Reoxcyn Discoveries Group, Inc. Method of modulating fatty acid mobilization and oxidation
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
LT2825037T (lt) 2012-03-16 2019-08-12 Regeneron Pharmaceuticals, Inc. Graužikai, ekspresuojantys ph jautrias imunoglobulino sekas
WO2014062837A1 (en) * 2012-10-16 2014-04-24 GenEon Technologies LLC Electrochemical activation of water
US20150099010A1 (en) * 2013-10-07 2015-04-09 Reoxcyn Discoveries Group, Inc Redox signaling gel formulation
CN104846075B (zh) * 2015-03-31 2017-09-29 温州医科大学 基于检测外周血线粒体dna氧化损伤评价体内氧化应激的方法
JP6472521B2 (ja) * 2015-07-21 2019-02-20 株式会社東芝 電解セルおよびこの電解セルを備える電解水生成装置
EP3606527A1 (en) * 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy
KR102493526B1 (ko) * 2017-04-14 2023-01-31 에보쿠아 워터 테크놀로지스 엘엘씨 동심 관형 전기 화학 전지를 위한 내부 전기 연결
CN109534528B (zh) * 2018-11-20 2021-11-12 新昌县泰如科技有限公司 一种环丙贝特工艺废水的处理方法
RU2712614C1 (ru) * 2019-03-12 2020-01-29 Федеральное государственное бюджетное научное учреждение "Поволжский научно-исследовательский институт производства и переработки мясомолочной продукции" (ГНУ НИИММП) Способ получения католитов-антиоксидантов электроактивированных водных растворов солей и их хранение

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984303A (en) 1975-07-02 1976-10-05 Diamond Shamrock Corporation Membrane electrolytic cell with concentric electrodes
US4177116A (en) * 1977-06-30 1979-12-04 Oronzio DeNora Implanti Elettrochimici S.p.A. Electrolytic cell with membrane and method of operation
IT1114820B (it) 1977-06-30 1986-01-27 Oronzio De Nora Impianti Cella elettrolitica monopolare a membrana
US5234563A (en) 1992-06-01 1993-08-10 Janix Kabushiki Kaisha Electrolytic ionized water producer of a continuous type
JP3285978B2 (ja) 1992-11-27 2002-05-27 ティーディーケイ株式会社 飲料水電解用電極およびその製造方法ならびにイオン水生成装置
JP2737643B2 (ja) * 1994-03-25 1998-04-08 日本電気株式会社 電解活性水の生成方法および生成装置
JP3468835B2 (ja) * 1994-05-09 2003-11-17 ホシザキ電機株式会社 電解水生成装置
US6117285A (en) * 1994-08-26 2000-09-12 Medical Discoveries, Inc. System for carrying out sterilization of equipment
JP2003525217A (ja) * 1999-10-22 2003-08-26 メルク エンド カムパニー インコーポレーテッド 肥満治療用薬剤
US6572902B2 (en) * 2001-04-25 2003-06-03 Advanced H2O, Inc. Process for producing improved alkaline drinking water and the product produced thereby
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
EP1579037A4 (en) 2002-03-06 2008-02-13 Univ Georgia Res Found METHOD AND APPARATUS FOR ELECTROLYSIS OF WATER
US20060032819A1 (en) * 2002-07-17 2006-02-16 Peter Nunn Water treatment device for electrolyzing, magnetizing, and re-resonating water
JP2004058006A (ja) * 2002-07-31 2004-02-26 First Ocean Kk 電解水製造方法
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
US7230016B2 (en) * 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
JP2008501027A (ja) * 2004-05-28 2008-01-17 メルク　エンド　カムパニー　インコーポレーテッド 抗糖尿病活性をもつベンゾ尿素
US20060003410A1 (en) * 2004-06-10 2006-01-05 Lee-Ming Chuang Prostaglandin reductase
RU2252920C1 (ru) * 2004-06-28 2005-05-27 Государственное научное учреждение Поволжский научно-исследовательский институт эколого-мелиоративных технологий Установка для электрохимической активации питьевой и оросительной воды
US8425756B2 (en) * 2004-10-08 2013-04-23 Electric Aquagenics Unlimited Apparatus and method for producing electrolyzed water
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
EP1863502B1 (en) * 2005-03-23 2018-09-12 Sonoma Pharmaceuticals, Inc. Method of treating skin ulcers using oxidative reductive potential water solution
US7588488B2 (en) * 2005-04-01 2009-09-15 Electric Aquagenics Unlimited Electrolyzed water treatment for poultry products
RU2008122547A (ru) * 2005-11-07 2009-12-20 Айрм Ллк (Bm) Соединения и композиции как модуляторы арпп (активированных рецепторов пролифератора пероксисом)
US8025787B2 (en) * 2006-02-10 2011-09-27 Tennant Company Method and apparatus for generating, applying and neutralizing an electrochemically activated liquid
DE102006028168A1 (de) * 2006-06-16 2007-12-20 Uhde Gmbh Vorrichtung zur elektrochemischen Wasseraufbereitung
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
WO2009054504A1 (ja) * 2007-10-24 2009-04-30 Suntory Holdings Limited ペルオキシソーム増殖剤応答性受容体（ｐｐａｒ）のリガンド剤
US20090110749A1 (en) * 2007-10-30 2009-04-30 Medical Management Research, Inc. Method and apparatus for producing a stabilized antimicrobial non-toxic electrolyzed saline solution exhibiting potential as a therapeutic
US8367120B1 (en) * 2007-10-31 2013-02-05 Reoxcyn Discoveries Group, Inc. Method and apparatus for producing a stablized antimicrobial non-toxic electrolyzed saline solution exhibiting potential as a therapeutic
EP2315724A2 (en) * 2008-06-19 2011-05-04 Tennant Company Electrolysis cell having electrodes with various-sized/shaped apertures
CN101371807A (zh) * 2008-07-19 2009-02-25 冯文昌 一种水温加氧气治疗癌症治疗器具
JP5355572B2 (ja) * 2008-07-31 2013-11-27 三菱電機株式会社 殺菌・抗菌装置
FR2940289B1 (fr) * 2008-12-23 2014-09-12 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas
WO2010111208A1 (en) * 2009-03-23 2010-09-30 University Of Miami Mitochondrial inhibitors and uses thereof
JP2012531440A (ja) * 2009-06-26 2012-12-10 エリック カーツ， 水溶性食餌脂肪酸
CA2780921A1 (en) * 2009-12-04 2011-06-09 Technologie Biolactis Inc. 15468 Method of regulating ppar, obesity related pathways and their associated metabolic impact
WO2011120923A1 (en) * 2010-03-30 2011-10-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
JP5770449B2 (ja) * 2010-10-20 2015-08-26 株式会社Kri ＰＰＡＲα活性化剤
CN102320684B (zh) * 2011-08-25 2013-05-29 洪韫麒 一种连续生成高氧化还原性水的反应器

Also Published As

Publication number Publication date
RU2636483C2 (ru) 2017-11-23
RU2015114716A (ru) 2016-11-10
EP2897613A4 (en) 2016-03-30
US9962404B2 (en) 2018-05-08
JP6314142B2 (ja) 2018-04-18
CN104936594A (zh) 2015-09-23
WO2014046722A1 (en) 2014-03-27
US20150246071A1 (en) 2015-09-03
WO2014046697A1 (en) 2014-03-27
JP2015530405A (ja) 2015-10-15
CN104903494B (zh) 2017-11-03
MX2015003700A (es) 2015-10-30
EP2898116A4 (en) 2016-06-01
CN104903494A (zh) 2015-09-09
EP2897613A1 (en) 2015-07-29
RU2015114800A (ru) 2016-11-10
EP3130564A1 (en) 2017-02-15
US20150246832A1 (en) 2015-09-03
JP2015534608A (ja) 2015-12-03
EP2898116A1 (en) 2015-07-29

Similar Documents

Publication Publication Date Title
PH12019502292A1 (en) Methods and compositions for treatment of a genetic condition
MX2015003701A (es) Composiciones para tratamiento.
PH12015500525A1 (en) Formulations of enzalutamide
HK1217289A1 (zh) 使用細菌治療癌症的組合物和方法
HUE041553T2 (hu) Lizoszomális tárolási betegségek (LSD) kezelése és génterápia
PH12014502513A1 (en) Nampt inhibitors
MX2014013752A (es) Inhibidores de nampt.
MX353299B (es) Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.
IN2014DN11201A (es)
DK3292875T3 (en) Compositions and methods for treating diseases
IN2015DN01151A (es)
HK1206387A1 (en) Organic compositions to treat kras-related diseases kras
EP2812451A4 (en) METHODS AND COMPOSITIONS RELATING TO ROS1 FUSIONS FOR DIAGNOSING AND TREATING CANCER
IL234606B (en) Innovative methods and compounds for the treatment of diseases
MX2016005393A (es) Metodos para tratar vhc.
PL2892556T3 (pl) Kompozycje i sposoby odnoszące się do leczenia chorób
EP3221351A4 (en) Methods and compositions for cancer treating conditions relating to over expressions of epha2
EP2709632A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
EP2879495A4 (en) COMPOSITIONS AND METHODS OF TREATING NEUROPSYCHOLOGICAL DEFICIENCIES
EP2928456A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna
SG11201504779YA (en) Methods and compositions relating to treatment of cancer
EP2825184A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN
AU2012902296A0 (en) Compositions for Therapy and Methods of Treatment
LV14738A (lv) Kardiovaskulāras iedarbības preparāts